Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 5Other solid neoplasm 3Gynecologic 3Other hematologic neoplasm 2Lymphoid 2Genitourinary 2Tumor-Agnostic 1Thoracic 1Plasma cell 1Head & Neck 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Recurrent Malignant Solid Neoplasm 1Advanced Solid Tumors 1Advanced Solid Tumor 1

Interventions

Cisplatin 81Gemcitabine 58Carboplatin 57Irinotecan 56Paclitaxel 53Pemetrexed 47Docetaxel 39Nivolumab 33Fluorouracil 30Bevacizumab 27pembrolizumab 25Cyclophosphamide 24Capecitabine 24Oxaliplatin 22Leucovorin 21Topotecan 19durvalumab 17Erlotinib Hydrochloride 17Sorafenib 16Everolimus 16Etoposide 16Bortezomib 16Ipilimumab 15Injections 15Sunitinib 14Filgrastim 14Early Intervention, Educational 14atezolizumab 13alvocidib 13Sirolimus 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × sapanisertib × Other solid neoplasm × Clear all
NCT03154294 2024-07-26

Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors

Avera McKennan Hospital & University Health Center

Phase 1 Completed
19 enrolled 16 charts
Other solid neoplasm

Advanced Solid Tumor

NCT02197572 2023-01-23

Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors

Calithera Biosciences, Inc

Phase 1 Completed
44 enrolled 25 charts
Other solid neoplasm

Advanced Solid Tumors

NCT03430882 2022-06-21

Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors

M.D. Anderson Cancer Center

Phase 1 Completed
35 enrolled
Other solid neoplasm

Recurrent Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡